Actavis/Watson divest four generics to Novartis' Sandoz
Executive Summary
Watson Pharmaceuticals Inc. and Actavis Group are divesting four products to Novartis AG’s Sandoz (generics) in order to comply with the FTC’s requirements to complete Watson's $5.6bn acquisition of Actavis.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
Deal Status
- Final
Deal Type
-
Alliance
- Marketing (Licensing)
- Product Purchase
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice